Sign in

ASTRAZENECA (AZN)

AstraZeneca (AZN) is a global, science-led biopharmaceutical company headquartered in Cambridge, UK. The company focuses on the discovery, development, and commercialization of prescription medicines to address unmet medical needs. Its portfolio spans innovative treatments in oncology, rare diseases, and biopharmaceuticals, with a strong emphasis on improving patient outcomes through cutting-edge research and strategic collaborations.

  1. Oncology - Develops innovative cancer treatments, including targeted therapies like Tagrisso and Iressa for lung cancer, and immuno-oncology drugs such as Imfinzi and Imjudo. Collaborates on next-generation therapies like Enhertu and Orpathys.

    • Tagrisso - Targets EGFR-mutated lung cancer.
    • Imfinzi - Focuses on immuno-oncology applications.
    • Enhertu - A HER2-directed antibody-drug conjugate developed with Daiichi Sankyo.
  2. Cardiovascular, Renal & Metabolism (CVRM) - Focuses on treatments for chronic cardiovascular diseases, renal conditions, and metabolic disorders. Key products include Farxiga for heart failure and Lokelma for hyperkalemia.

  3. Rare Diseases - Specializes in therapies for conditions driven by the complement cascade, such as Ultomiris for generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria. Operates through its Alexion Pharmaceuticals division.

    • Ultomiris - A long-acting C5 complement inhibitor.
    • Strensiq - Treats hypophosphatasia, a rare metabolic disorder.
  4. Respiratory & Immunology (R&I) - Develops therapies for respiratory diseases and immune system disorders, including Symbicort for asthma and COPD, and Tezspire for severe asthma.

  5. Vaccines & Immune Therapies (V&I) - Focuses on vaccines and treatments for infectious diseases, including Beyfortus for respiratory syncytial virus (RSV) and Synagis for pediatric RSV prevention.

  6. Other Medicines - Includes legacy products such as Nexium for acid reflux and other established medicines.

You might also like

NamePositionExternal RolesShort Bio

Aradhana Sarin

ExecutiveBoard

CFO and Executive Director

Board Member of the American Red Cross; Independent Director of Anheuser-Busch InBev.

CFO since 2021, previously CFO at Alexion; trained as a medical doctor and holds an MBA from Stanford.

Pascal Soriot

ExecutiveBoard

CEO and Executive Director

Board Member of the Sustainable Markets Initiative Limited.

CEO since 2012, led AZN's growth, including R&D advancements and COVID-19 response; knighted in 2022.

David Fredrickson

Executive

EVP, Oncology Business Unit

None.

EVP since 2017, led oncology portfolio growth, including Tagrisso and Imfinzi.

Iskra Reic

Executive

EVP, International

Board Member of myTomorrows; Steering Committee Member of PHSSR.

EVP since 2024, previously led Vaccines & Immune Therapies; drives growth in Emerging Markets.

Jeff Pott

Executive

Chief HR Officer, Chief Compliance Officer, and General Counsel

None.

Joined AZN in 1995; oversees HR, compliance, and legal functions.

Leon Wang

Executive

EVP, International and China President

None.

EVP since 2017, led AZN's growth in China and Emerging Markets; established Shanghai R&D center.

Marc Dunoyer

Executive

CEO of Alexion, AstraZeneca Rare Disease; Chief Strategy Officer

None.

CEO of Alexion since 2021; led integration of Alexion into AZN and expanded rare disease pipeline.

Pam Cheng

Executive

EVP, Global Operations and IT; Chief Sustainability Officer

None.

EVP since 2015, leads sustainability strategy; recognized on TIME100 Climate list.

Ruud Dobber

Executive

EVP, BioPharmaceuticals Business Unit

None.

EVP since 2019, responsible for CVRM, R&I, and neuroscience; key driver of product growth like Farxiga.

Sharon Barr

Executive

EVP, BioPharmaceuticals R&D

None.

EVP since 2023, previously SVP at Alexion; oversees CVRM and R&I R&D.

Susan Galbraith

Executive

EVP, Oncology R&D

None.

EVP since 2020, oversees oncology R&D; key contributor to Imfinzi and capivasertib development.

Andreas Rummelt

Board

Non-Executive Director

Chair and Managing Partner of InterPharmaLink AG.

Director since 2021, former CEO of Sandoz and Novartis executive; extensive experience in generics and pharma.

Deborah DiSanzo

Board

Non-Executive Director

President of Best Buy Health; teaches AI in Health at Harvard.

Director since 2017, over 30 years of experience in healthcare and technology; former GM of IBM Watson Health.

Diana Layfield

Board

Non-Executive Director

Chair of British International Investment; Council Member of LSHTM.

Director since 2020, extensive global business experience; currently General Manager, International Search at Google.

Marcus Wallenberg

Board

Non-Executive Director

Chair of SEB, Saab, and FAM AB; Vice-Chair of Investor AB and EQT AB.

Director since 1999, extensive international business experience across multiple industries.

Michel Demar\u00e9

Board

Non-Executive Chair of the Board

Non-Executive Director at Vodafone Group plc and Louis Dreyfus International; Chair of IMD.

Chair since 2023, previously Non-Executive Director; extensive experience in finance and governance.

Nazneen Rahman

Board

Non-Executive Director

CEO of YewMaker; Director of Sustainable Medicines Partnership.

Director since 2017, expert in rare diseases and sustainable healthcare; former Professor of Genetics at ICR.

Philip Broadley

Board

Senior Independent Non-Executive Director

Chair-designate of Lancashire Holdings; Senior Independent Director of Legal & General.

Director since 2017, extensive finance experience; previously Group Finance Director at Prudential and Old Mutual.

Sheri McCoy

Board

Non-Executive Director

Chair of Dechra Pharmaceuticals; Board Member at Stryker, Kimberly-Clark, and Sail Biomedicines.

Director since 2017, former CEO of Avon and Vice-Chairman at J&J; extensive leadership in pharma and consumer health.

Tony Mok

Board

Non-Executive Director

Non-Executive Director of HUTCHMED; Member of Prenetics Scientific Advisory Board.

Director since 2019, leading oncologist and researcher; Chair of Clinical Oncology at CUHK.

  1. You have set a goal to reach mid-30s operating margins by 2026, but ended 2024 just above 31%, with guidance suggesting minimal leverage in 2025. How do you plan to achieve the remaining 400 basis points improvement in such a short timeframe?

  2. Airsupra was anticipated to be a multi-blockbuster drug, yet its launch has been relatively soft with little improvement in the fourth quarter. What strategies are you implementing to accelerate its growth and overcome the access challenges you've faced?

  3. Given the investigations and market pressures in China, including anticipated VBP inclusion for key products, how confident are you in your 2025 growth projections for the Chinese market, and what risks should investors be aware of?

  4. Can you discuss the potential financial impact of the customs duty issue in China, and clarify whether there is a risk of significant fines or liabilities that could affect your financial results?

  5. With the upcoming Part D redesign in 2025 affecting products like Calquence, how do you plan to mitigate the impact on your oncology portfolio and maintain the growth trajectory amid these legislative headwinds?

Research analysts who have asked questions during ASTRAZENECA earnings calls.

James Gordon

JPMorgan Chase & Co.

4 questions for AZN

Also covers: ARGX, GRFS, GSK

Luisa Hector

Berenberg

4 questions for AZN

Also covers: ABBV, BMY, MRK +1 more

Rajan Sharma

Goldman Sachs Group, Inc.

4 questions for AZN

Also covers: ARGX, AUTL, CVAC +6 more

Sachin Jain

Bank of America

4 questions for AZN

Also covers: GMAB, GSK, NVO +2 more

Matthew Weston

UBS Group AG

3 questions for AZN

Also covers: GSK, NVS, SNY

Mattias Häggblom

Handelsbanken

3 questions for AZN

Also covers: GNNDY

Peter Verdult

Citigroup Inc.

3 questions for AZN

Also covers: EVO, GMAB, GRFS +4 more

Seamus Fernandez

Guggenheim Partners

3 questions for AZN

Also covers: AMLX, ARCT, ARQT +9 more

Gonzalo Artiach Castanon

Danske Bank

2 questions for AZN

Sarita Kapila

Morgan Stanley

2 questions for AZN

Also covers: GSK, SNY

Simon Baker

Redburn Atlantic

2 questions for AZN

Also covers: AUTL, BNTX, GILD +5 more

Steve Scala

Cowen

2 questions for AZN

Also covers: ABBV, BMY, GSK +6 more

Emily Field

Barclays

1 question for AZN

Also covers: GMAB, GSK, NVO +2 more

Emmanuel Papadakis

Deutsche Bank

1 question for AZN

Also covers: NVO, NVS, SNY

Eric Le Berrigaud

Stifel

1 question for AZN

Also covers: NVS, SNY

Gonzalo Artiach

Danske Bank

1 question for AZN

Jo Walton

UBS

1 question for AZN

Also covers: GSK, NVO, NVS +1 more

Justin Smith

Bernstein

1 question for AZN

Also covers: SCWO

Justin Steven Smith

Bernstein

1 question for AZN

Also covers: GSK

Mark Purcell

Morgan Stanley

1 question for AZN

Also covers: GSK, NVS

Michael Leuchten

Jefferies

1 question for AZN

Also covers: GSK, NVO, NVS

Peter Welford

Jefferies

1 question for AZN

Also covers: GSK, NVO, NVS +1 more

Rajesh Kumar

HSBC

1 question for AZN

Also covers: BZLFY, LLY, NVO +2 more

Richard Parkes

BNP Paribas Exane

1 question for AZN

Also covers: GSK, NVO, NVS

Timothy Anderson

BofA Securities

1 question for AZN

Also covers: ABBV, AMGN, BIIB +10 more

Notable M&A activity and strategic investments in the past 3 years.

CompanyYearDetails

Gracell Biotechnologies, Inc.

2024

AstraZeneca acquired Gracell for an upfront cash payment of about $1.0 billion, with a total transaction value of approximately $1.2 billion that included additional contingent value; the deal brought in the clinical-stage FasTCAR-enabled BCMA/CD19 dual-targeting CAR‑T therapy (GC012F) along with $209 million in cash equivalents, strengthening its cell therapy pipeline.

Icosavax, Inc.

2024

The acquisition was executed via a tender offer at $15.00 per share cash upfront plus a contingent value right up to $5.00 per share for a total potential value of around $1.1 billion; it bolsters AstraZeneca’s Vaccines & Immune Therapies portfolio with Icosavax’s Phase III-ready VLP vaccine candidate IVX-A12 targeting RSV and hMPV.

Fusion Pharmaceuticals Inc.

2024

Completed for approximately $2.4 billion—$2.051 billion upfront and $144 million in contingent regulatory milestone payments—this deal adds next-generation radioconjugates (notably FPI-2265) to AstraZeneca’s oncology pipeline and accelerates its radiopharmaceutical manufacturing capabilities.

Amolyt Pharma

2024

AstraZeneca acquired Amolyt Pharma for a total consideration of up to $1.05 billion (with $800 million upfront and up to $250 million contingent on milestones) to enhance its Rare Disease pipeline and expand its bone metabolism franchise with the Phase III candidate eneboparatide (AZP‑3601) for hypoparathyroidism.

CinCor Pharma, Inc.

2023

The acquisition was structured as a tender offer with an upfront cash payment of about $1.3 billion (at $26 per share plus a $10 contingent per share), totaling approximately $1.8 billion, and included cash/marketable securities valued at $522 million; it adds the aldosterone synthase inhibitor baxdrostat (CIN‑107) to complement its cardiorenal strategy.

Neogene Therapeutics, Inc.

2023

Completed for a total consideration of up to $320 million (with an initial $200 million cash payment and up to $120 million in contingent payments), the acquisition advances AstraZeneca’s cell therapy portfolio by adding next‑generation T‑cell receptor therapies targeting solid tumors along with significant intangible assets and goodwill.

TeneoTwo, Inc.

2022

AstraZeneca acquired TeneoTwo, paying $100 million upfront and agreeing to up to $1.165 billion in milestone payments (combining R&D and commercial milestones), to secure its Phase I CD19/CD3 T‑cell engager TNB‑486 which is aimed at treating B‑cell hematologic malignancies without including transfer of people or facilities.

Recent press releases and 8-K filings for AZN.

AstraZeneca reports positive Enhertu Phase III trial results for early breast cancer
·$AZN
Product Launch
New Projects/Investments
  • On September 29, 2025, AstraZeneca announced that Enhertu demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) in the DESTINY-Breast05 Phase III trial.
  • The trial evaluated Enhertu against T-DM1 in patients with HER2-positive early breast cancer who had residual invasive disease after neoadjuvant treatment and a high risk of recurrence.
  • This marks the second positive Phase III trial for Enhertu in the HER2-positive early breast cancer setting, reinforcing its potential as a foundational treatment option in curative-intent early breast cancer.
  • The safety profile of Enhertu in DESTINY-Breast05 was consistent with its known profile, and the data will be presented at ESMO 2025 on October 18.
6 days ago
AstraZeneca to Harmonize Listing Structure
·$AZN
Delisting/Listing Issues
  • AstraZeneca plans to harmonise its share listing structure across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE).
  • This will involve a direct listing of AstraZeneca ordinary shares on the NYSE, replacing the existing US listing of AstraZeneca ADRs on Nasdaq.
  • The company will remain headquartered and tax resident in the UK and continue to be included in the FTSE 100 and OMX Stockholm 30 indices.
  • A General Meeting is scheduled for Monday, November 3, 2025, at 2:30 p.m. (GMT) for shareholders to vote on the proposed Harmonised Listing Structure.
6 days ago
AstraZeneca PLC Proposes Harmonised Listing Structure with NYSE Direct Listing
·$AZN
Delisting/Listing Issues
Proxy Vote Outcomes
  • AstraZeneca PLC is proposing a Harmonised Listing Structure that includes a direct listing of its shares on the NYSE, replacing its current US listing of American Depositary Shares (ADSs) on Nasdaq.
  • This strategic move aims to widen the investor pool, especially among US domestic institutional and retail investors, as the US market represented 43% of total revenue in 2024 and is expected to reach 50% by 2030.
  • Shareholder approval for amendments to the company's articles of association is required at a General Meeting on November 3, 2025, with the new structure anticipated to be effective by February 2, 2026, if approved.
  • The implementation will involve the termination of the existing ADR Programme and a migration of the primary settlement system from CREST to DTC.
6 days ago
AstraZeneca's Koselugo Recommended for EU Approval
·$AZN
Product Launch
New Projects/Investments
  • AstraZeneca's Koselugo (selumetinib) has received a positive recommendation for approval in the European Union (EU) from the Committee for Medicinal Products for Human Use (CHMP).
  • The recommendation is for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with neurofibromatosis type 1 (NF1).
  • This positive opinion is based on results from the KOMET Phase III trial, which showed a statistically significant objective response rate (ORR) of 20% for Koselugo compared to 5% with placebo by cycle 16.
  • Koselugo is already approved for this indication in adults in Japan and other countries, and for paediatric patients in the US, EU, Japan, and China.
Sep 22, 2025, 11:46 AM
AstraZeneca's Tezspire Recommended for EU Approval in CRSwNP
·$AZN
Product Launch
  • AstraZeneca and Amgen's Tezspire (tezepelumab) has received a positive recommendation for approval in the European Union (EU) by the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
  • The recommendation is based on results from the WAYPOINT Phase III trial, which showed Tezspire significantly reduced nasal polyp severity and nasal congestion, nearly eliminated the need for surgery (98%), and significantly reduced systemic corticosteroid use (89%) compared to placebo.
  • Regulatory applications for Tezspire in CRSwNP are also currently under review in the US, China, Japan, and several other countries.
  • Tezspire is already approved for the treatment of severe asthma in the US, EU, Japan, and more than 60 countries, having treated over 100,000 patients since 2021.
Sep 22, 2025, 11:39 AM
AstraZeneca's Saphnelo TULIP-SC Phase III Trial Meets Primary Endpoint
·$AZN
Product Launch
New Projects/Investments
  • AstraZeneca's Saphnelo (anifrolumab) self-administration TULIP-SC Phase III trial met its primary endpoint in patients with systemic lupus erythematosus (SLE) based on an interim analysis.
  • The subcutaneous administration of Saphnelo demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo, with a safety profile consistent with the known intravenous infusion.
  • The interim results are under regulatory review and will be presented at the American College of Rheumatology (ACR) Convergence 2025 annual meeting, October 24-29, 2025.
  • AstraZeneca is actively working with regulatory authorities to bring this new, more flexible administration option to patients.
Sep 17, 2025, 11:46 AM
AstraZeneca provides update on RESOLUTE Phase III trial for Fasenra
·$AZN
New Projects/Investments
  • The RESOLUTE Phase III trial of AstraZeneca's Fasenra (benralizumab) for chronic obstructive pulmonary disease (COPD) did not achieve statistical significance in its primary endpoint, despite showing numerical improvement.
  • AstraZeneca plans to analyse the full data set from RESOLUTE to further understand the results, which will be shared with the scientific community.
  • Fasenra is currently approved as an add-on maintenance treatment for severe eosinophilic asthma (SEA) in over 80 countries and for eosinophilic granulomatosis with polyangiitis (EGPA) in over 60 countries.
  • Separately, the NATRON Phase III trial evaluating Fasenra in hypereosinophilic syndrome (HES) successfully met its primary endpoint.
Sep 17, 2025, 11:11 AM
AstraZeneca Presents Positive Baxdrostat Phase III Data and $5 Billion Plus Market Opportunity
·$AZN
Product Launch
New Projects/Investments
Guidance Update
  • AstraZeneca presented positive Phase III data for Baxdrostat, a potential first-in-class aldosterone inhibitor for hard-to-control hypertension, demonstrating significant blood pressure reduction and a favorable tolerability profile.
  • In the Bax HTN trial, Baxdrostat reduced seated office systolic blood pressure by 8.7 mmHg (1mg dose) and 9.8 mmHg (2mg dose) placebo-corrected from baseline to week 12.
  • The company anticipates Baxdrostat to be a $5 billion plus opportunity, with roughly a fifty-fifty split between monotherapy and fixed-dose combinations.
  • AstraZeneca has ongoing Phase III trials for Baxdrostat in combination with dapagliflozin for chronic kidney disease and heart failure prevention, with data expected beyond 2026.
Sep 1, 2025, 2:29 PM
AstraZeneca Pledges Significant US Investment Amidst Tariff Discussions
·$AZN
New Projects/Investments
  • Former President Donald Trump announced plans to implement tariffs on imported drugs, starting small and potentially increasing to 150% within 18 months and then to 250%.
  • The initiative aims to incentivize drug manufacturers to increase domestic production in the United States.
  • AstraZeneca has committed to investing $50 billion to expand its operations in the US, aligning with the push for increased domestic manufacturing.
  • A framework agreement between the US and EU currently sets tariffs on drugs at zero, but specifies a cap of 15% if Washington raises them following an import investigation.
Aug 6, 2025, 4:36 AM
AstraZeneca Announces $50 Billion US Investment Plan
·$AZN
New Projects/Investments
Guidance Update
Hiring
  • AstraZeneca plans to invest $50 billion in the United States by 2030 for medicines manufacturing and R&D.
  • The cornerstone of this investment is a proposed new multi-billion dollar drug substance manufacturing centre in the Commonwealth of Virginia, which will be the company's largest single manufacturing investment globally.
  • This investment supports AstraZeneca's ambition to reach $80 billion in total revenue by 2030, with 50% of that revenue generated in the US.
Jul 22, 2025, 12:00 AM